SCHEMBL2004126

SCHEMBL2004126

CCCCCCCCCCCCCC(=O)OC(CCCCCCCCCCCC)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.59
MAPK1 P28482 4/20 0.56
MAPT P10636 3/20 0.56
ALDH1A1 P00352 1/20 0.53
CYP1A2 P05177 2/20 0.49
MEN1 O00255 2/20 0.49
GMNN O75496 2/20 0.49
HSP90AA1 P07900 2/20 0.49
BLM P54132 2/20 0.49
KMT2A Q03164 2/20 0.49
NPSR1 Q6W5P4 2/20 0.49
NR1H4 Q96RI1 2/20 0.49
TP53 P04637 1/20 0.49
CYP2C9 P11712 1/20 0.49
TSHR P16473 1/20 0.49
HIF1A Q16665 1/20 0.49
PRKCA P17252 1/20 0.49
PRKCE Q02156 1/20 0.49
PRKCQ Q04759 1/20 0.49
PRKCD Q05655 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9406999 1.00 LMNA (0.59) LMNAMAPK1MAPTALDH1A1CYP1A2
SCHEMBL7507925 1.00 LMNA (0.59) LMNAMAPK1MAPTALDH1A1CYP1A2
SCHEMBL9406782 1.00 LMNA (0.59) LMNAMAPK1MAPTALDH1A1CYP1A2
SCHEMBL9406778 1.00 LMNA (0.59) LMNAMAPK1MAPTALDH1A1CYP1A2
SCHEMBL9195199 1.00 LMNA (0.59) LMNAMAPK1MAPTALDH1A1CYP1A2
SCHEMBL11909127 1.00 LMNA (0.59) LMNAMAPK1MAPTALDH1A1CYP1A2
SCHEMBL4204474 1.00 LMNA (0.59) LMNAMAPK1MAPTALDH1A1CYP1A2
SCHEMBL4311172 1.00 LMNA (0.59) LMNAMAPK1MAPTALDH1A1CYP1A2
SCHEMBL9218791 1.00 LMNA (0.59) LMNAMAPK1MAPTALDH1A1CYP1A2
SCHEMBL2679977 1.00 LMNA (0.59) LMNAMAPK1MAPTALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960523-B2 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor CORIXA CORPORATION (US) 2011-06-14 US disclosed
US-20080033155-A1 PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR CORIXA CORPORATION (US) 2008-02-07 US disclosed
US-7288640-B2 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor CORIXA CORPORATION (US) 2007-10-30 US disclosed
WO-2006012425-A2 PROCESSES FOR THE PRODUCTION OF AMINOALKYL GLUCOSAMINIDE PHOSPHATE AND DISACCHARIDE IMMUNOEFFECTORS, AND INTERMEDIATES THEREFOR CORIXA CORPORATION (US) 2006-02-02 WO disclosed
US-20050107600-A1 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor CORIXA CORPORATION, A CORPORATION OF THE STATE OF DELAWARE (US) 2005-05-19 US disclosed
US-5352811-A To produce homoallylic alcohol, acylation, oxidation of double bond E. I. DU PONT DE NEMOURS AND COMPANY (US) 1994-10-04 US disclosed
US-5278300-A Pharmaceuticals with immunopotentiation, antitumor, mitogenic, tumor necrosis factor-inducing, interferon-inducing activity; low toxicity JAPAN TOBACCO, INC. (JP) 1994-01-11 US disclosed
US-5158941-A Lipid A analog as stimulant for production of interleukin-1 in human monocytes and tumor cell growth inhibitor E. I. DU PONT DE NEMOURS AND COMPANY (US) 1992-10-27 US disclosed
US-4746742-A IMMUNOLOGY, ANTI-TUMOR TOHO YAKUHIN KOGYO KABUSHIKI KAISHA (JP) 1988-05-24 US disclosed
EP-0224260-A2 Analogs of nonreducing monosaccharide moiety of lipid A Toho Yakuhin Kogyo Kabushiki Kaisha (JP) 1987-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107600-A1 Processes for the production of aminoalkyl glucosaminide phosphate and disaccharide immunoeffectors, and intermediates therefor DDOST, AGL, GALE LMNA 4696/4885MAPK1 3417/4885MAPT 4448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.